# OnCo record craniopharyngioma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/craniopharyngioma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "craniopharyngioma" ;
  schema:name "Craniopharyngioma"@en ;
  schema:alternateName "Adamantinomatous craniopharyngioma"@en, "Papillary craniopharyngioma"@en, "Childhood craniopharyngioma"@en ;
  schema:description "Craniopharyngioma is a benign but destructive brain tumour growing from embryonic remnants beside the pituitary gland and hypothalamus. Surgery, or limited surgery plus radiotherapy, cures most people, but the price can be lifelong hormone deficiency and severe obesity. The adult (papillary) form carries a BRAF mutation and shrinks markedly with BRAF and MEK inhibitors, its first drug treatment."@en ;
  schema:url <https://onco.cc/cancers/craniopharyngioma/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Craniopharyngioma> ;
  schema:citation <https://www.cancer.gov/types/brain/hp/child-cranio-treatment-pdq>, <https://doi.org/10.1016/S1470-2045(23)00492-9>, <https://doi.org/10.1038/ng.2868> ;
  onco:tag "nci-coverage", "paediatric", "cns" ;
  onco:related <https://onco.cc/cancers/pituitary-tumours/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/>, <https://onco.cc/cancers/cns-germ-cell-tumours/>, <https://onco.cc/cancers/meningioma/> ;
  onco:technologies <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/setmelanotide/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/companies/alliance-oncology/> ;
  onco:institutions <https://onco.cc/institutions/st-jude/> ;
  onco:pathways <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/inflammation-nfkb/> ;
  onco:terms <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-brastianos-nat-genet/> ;
  onco:pipeline <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/glp1-agonists-cancer-risk/> ;
  onco:standardOfCare <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/technologies/survivorship-care-plan/> .